Author:

• Camila Marcelino Loureiro - Loureiro, C.M - <camila.loureiro@usp.br>
ORCID: https://orcid.org/0000-0002-0239-5064

Co-author(s):

• Fabiana Corsi-Zuelli - Corsi-Zuelli, F - <fabiana.zuelli@usp.br>
ORCID: https://orcid.org/0000-0001-9202-3987
• Helene Aparecida Fachim - Fachim, H.A - <hfachim@yahoo.com.br>
ORCID: https://orcid.org/0000-0003-3818-3167
• Rosana Shuhama - Shuhama, R - <roshuhama@gmail.com>
ORCID: https://orcid.org/0000-0001-7626-7543
• Natália Mota de Souza Chagas - Chagas, N.M.S - <nataliamotadesouzachagas@gmail.com>
ORCID: https://orcid.org/0000-0003-0984-9919
• Paulo Rossi Menezes - Menezes, P.R - <pmenezes@usp.br>
ORCID: https://orcid.org/0000-0001-6330-3314
• Cristina Marta Del-Ben - Del-Ben, C.M - <delben@fmrp.usp.br>
ORCID: https://orcid.org/0000-0003-0145-9975
• Paulo Louzada-Junior - Louzada-Junior, P - <plouzada@fmrp.usp.br>
ORCID: https://orcid.org/0000-0003-2585-3870

Abstract:

We investigated the feasibility of including plasma anti-NMDAR antibody screening in the assessment of first-episode psychosis patients in an early intervention programme in the Southern hemisphere. Anti-NMDAR IgG antibodies were assessed by ELISA in 166 patients (64.0% men), 166 matched population-based controls and 76 patients’ siblings (30.3% men). Fisher’s exact test and ANOVA were performed. Positive anti-NMDAR antibody patients were more often observed in bipolar disorder (10.0%) than schizophrenia (2.4%) or psychotic depression (3.1%), although no significant differences were observed. Our results are not conclusive regarding the inclusion of plasma anti-NMDAR IgG antibodies in differential diagnostic protocols for psychosis.

Keywords:

Antibodies anti-NMDAR, Bipolar disorder, Differential diagnosis, First-episode psychosis

Content:

Access Issue in Scielo

Other languages: